Skip to main content

KALA BIO, Inc.

KALA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001479419

No open-market purchases or sales by KALA BIO, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $1.21M in total; no superinvestor holds it.

Q3 2022 vs. Q2 2022

How the institutions holding KALA BIO, Inc. changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of KALA: Q2 2022 compared with Q3 2022
MeasureQ2 2022Q3 2022Change
Holders7056−14
Shares7.52M6.17M−1.36M (−18.0%)
Value$2.27M$1.36M−$909.1K (−40.1%)

New holders (4)

Institutions that held KALA BIO, Inc. at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to KALA in Q3 2022
InstitutionSharesValue% of portfolio
Tower Research Capital LLC (TRC)39,058$9.00K0.00%
Susquehanna Fundamental Investments, LLC16,733$4.00K0.00%
GSB Wealth Management, LLC20,000$4.00K0.00%
StoneX Group Inc.13,480$2.98K0.00%

Sold out (18)

Institutions that held KALA BIO, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.